Arboretum Ventures is a Michigan-based venture capital firm. It specializes in seed-stage, early-stage, mid-stage investments, and growth capital. The company seeks to invest in healthcare sector with a focus on services, medical devices, diagnostics; healthcare information technology, therapeutics, technology based healthcare services, and life science tools. The firm invests throughout the United States with a focus on Midwest and Michigan. It seeks to invest in companies with equity investment between $5 million and $15 million. Arboretum Ventures Jan Garfinkle in 2002 and is headquartered in Michigan.

Arboretum Ventures

Beringea is an international venture capital and private equity firm dedicated to finding, funding and nurturing exceptional companies in growth industries. Founded in 1988, the firm currently has more than 60 portfolio companies in a range of emerging sectors, including media, health care and life sciences, Internet technologies, advanced manufacturing, clean tech and specialized consumer goods. With capital, experience and offices in the U.S. and U.K., Beringea is in a unique position to offer entrepreneurs and their management teams the resources to develop strategy, evaluate growth opportunities, solve problems and build value. Beringea is the co-manager of the Michigan Growth Capital Partners Funds in the U.S., as well as the ProVen VCT family of funds in the UK, among others.

Beringea

Wolverine Venture Fund is a student-run venture capital fund.

Wolverine Venture Fund

The InvestMichigan! Program (the “Program”) is an initiative that makes capital available to successful entrepreneurs who create jobs in Michigan. Its principal goals are to generate strong returns for investors, provide assistance to growing Michigan companies, attract world class investment in the outstanding companies already present in Michigan, and encourage investors to locate their portfolio companies in Michigan. Investments are made across a broad range of industry sectors and investment stages, ranging from early-stage venture through mature companies.  The Funds are co-managed by Beringea, a Michigan-based venture capital firm experienced in geographically targeted investment programs, and GCM Grosvenor Private Markets. The objectives of the funds are to: Retain and attract growth businesses to Michigan; Nurture portfolio companies at each phase of development; Enhance Michigan’s reputation for entrepreneurship; Attract leading regional and national private equity and venture capital investment funds to Michigan, and Further develop Michigan’s entrepreneurial ecosystem  Portfolio companies that become part of the program and their management teams will be supported by the Business Leadership Council, led by Chairman Peter Karmanos and comprised of Michigan business leaders who offer support, guidance and access to business relationships.

InvestMichigan

North Coast's capitalization allows them to see a promising venture through all stages of their private funding needs. Although they co-invest with other venture capital firms, and corporate partners, they are often the first or sole venture investor in the companies they back.

North Coast Technology Investors

Turning innovation into health. Venture Investors seeks the next big things in healthcare. Based in the Midwest with open access to renowned research universities, and the vibrant communities that surround them, we target, uncover, and invest in extraordinary ideas that will shape the future of health and wellness. With decades of proven success, we’re fueling the future of what’s driving healthcare. Today, we have over $200 million in assets under management.

Venture Investors

Hopen Therapeutics is a private investment and management firm focused on helping early- to mid-stage life science developments achieve commercial success. We're interested in promising pharmaceutical and healthcare concepts, and offer idea owners three key advantages: ample funding, development and managerial expertise, and a broad network of industry relationships.

Hopen Life Science Ventures

Waycross Ventures is a venture capital firm. It is headquartered in Menlo Park, California.

Waycross Ventures

Delphinus Medical Technologies

Delphinus Medical Technologies develops, commercializes, sells, and services breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy.

Delphinus Medical Technologies, a spin-out from the Karmanos Cancer Institute, is a medical imaging company specializing in cancer detection. The company offers SoftVue, a 3D whole-breast ultrasound tomography system designed for early detection of breast cancer in women with dense breasts. SoftVue utilizes a proprietary Triple Acoustic Detection (TriAD) technology, which characterizes tissue by recording the reflection, speed, and direction of sound waves moving through the breast tissue. This patented circular array transducer technology delivers no radiation, requires no compression, and images the entire breast with a single scan.

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Delphinus Medical Technologies Awarded Technology Breakthrough From Premier, Inc.

Delphinus Medical Technologies, a spin-out from the Karmanos Cancer Institute, is a medical imaging company specializing in cancer detection. The company offers SoftVue, a 3D whole-breast ultrasound tomography system designed for early detection of breast cancer in women with dense breasts. SoftVue utilizes a proprietary Triple Acoustic Detection (TriAD) technology, which characterizes tissue by recording the reflection, speed, and direction of sound waves moving through the breast tissue. This patented circular array transducer technology delivers no radiation, requires no compression, and images the entire breast with a single scan.SoftVue was approved by the FDA in October 2021 as an adjunct to mammography for screening women with dense breasts. When paired with mammography, SoftVue has been shown to identify up to 20% more cancers while reducing false positives and decreasing unnecessary call-backs and biopsies in women with dense breasts.Key customers and partnershipsDelphinus primarily serves hospitals and imaging clinics across the US. The company has expanded its commercial footprint, with installations at sites like the Barbara Ann Karmanos Cancer Institute, East Alabama Medical Center, Corewell Health, and The University of Rochester Medical Center.

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

Delphinus Medical Technologies

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless